WHO alert, 14 May 2025
N°3/2025: Falsified IMFINZI (durvalumab) injection 500 mg/10 ml, three further lots
Last checked 20 September 2026. Some details are still being checked against the WHO annex.
On 14 May 2025 the WHO issued a second alert on falsified IMFINZI (durvalumab), identifying three further lot numbers of falsified 500 mg/10 ml vials that AstraZeneca confirmed it had not made. The alert followed N°5/2024 on lot BAVX, which an August 2025 update reported found in India, Pakistan and Uzbekistan. The countries in which the three additional lots were detected are not confirmed in our sources and should be verified against the alert text. Falsified cancer immunotherapy is dangerous because patients miss treatment while believing they are receiving it.
India link: Follows N°5/2024, whose falsified lot was later found in India; countries for these lots to be verified
WHO Medical Product Alert N°3/2025: Falsified IMFINZI (durvalumab) injection 500mg/10ml
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Products named
- IMFINZI (durvalumab) 500 mg/10 ml injection, three falsified lots (numbers: see WHO alert)
- Genuine product: AstraZeneca
Official sources and primary records
- WHO
- WHO